To investigate the wide range of therapeutic efficacy of ENb-TRAIL in different types of tumors, we tested ENb-TRAIL on a panel of EGFR amplified, mutated or wild type colon (HT29, HCT116), lung (Calu1, HCC827), and glioma (LN229, GBM6) cell lines with varying levels of EGFR, DR4 and DR5 expression levels (Fig. S1B,C). The gene discussed is TNFRSF10A; the disease is central nervous system cancer.